Palvella Therapeutics (PVLA) Operating Income Growth (5y) (2018 - 2026)

Palvella Therapeutics (PVLA) Operating Income Growth (5y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.84 Bn 467.05 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.01 Bn 61.26 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.93 Bn 50.74 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 Palvella Therapeutics 1.89 Bn 1.62 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -24.04%
Dec 31, 2025 1.85%
Sep 30, 2025 4.78%
Jun 30, 2025 -14.72%
Mar 31, 2025 -15.34%
Dec 31, 2024 -26.84%
Sep 30, 2024 -11.68%
Jun 30, 2024 24.97%
Mar 31, 2024 30.29%
Dec 31, 2023 25.05%
Sep 30, 2023 -8.63%
Jun 30, 2023 23.90%
Mar 31, 2023 -13.77%
Dec 31, 2022 -30.43%
Sep 30, 2022 -18.61%
Jun 30, 2022 -9.34%
Mar 31, 2022 1.41%
Dec 31, 2021 -11.42%
Sep 30, 2021 -25.21%
Jun 30, 2021 -23.66%